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Cell signallingGap junctions, composed of proteins from the connexin family, allow for intercellular communication
between cells in essentially all tissues. There are 21 connexin genes in the human genome and different
tissues express different connexin genes. Most connexins are known to be phosphoproteins. Phosphorylation
can regulate connexin assembly into gap junctions, gap junction turnover and channel gating. Given the
importance of gap junctions in development, proliferation and carcinogenesis, regulation of gap junction
phosphorylation in response to wounding, hypoxia and other tissue insults is proving to be critical for cellular
response and return to homeostasis. Connexin43 (Cx43) is themost widely and highly expressed gap junction
protein, both in cell culture models and in humans, thus more research has been done on it andmore reagents
to it are available. In particular, antibodies that can report Cx43 phosphorylation status have been created
allowing temporal examination of speciﬁc phosphorylation events in vivo. This review is focused on the use of
these antibodies in tissue in situ, predominantly looking at Cx43 phosphorylation in brain, heart, endothelium
and epithelium with reference to other connexins where data is available. These data allow us to begin to
correlate speciﬁc phosphorylation events with changes in cell and tissue function. This article is part of a
Special Issue entitled: The Communicating junctions, composition, structure and characteristics.ed protein kinase; PKC, protein
l junction; SDS-PAGE, sodium
MC, vascular smooth muscle
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The term gap junction refers to a structure consisting of a tightly
packed cluster of channels at the plasma membrane of one cell that
interacts with a matched set of channels in an opposing cell, effectively
connecting the cytoplasm of the two cells. Although different connexins
exhibit different permeabilities, typically molecules of less than 1000 Da
can transit through these channels including ions, simple sugars, amino
acids, nucleotides, short polypeptides and secondmessengers (e.g., Ca2+,
cAMP, cGMP, and IP3) [1–4]. Vertebrate gap junctions are composed of
proteins from the connexin family, which is comprised of 21members in
1986 L. Márquez-Rosado et al. / Biochimica et Biophysica Acta 1818 (2012) 1985–1992humans [5,6]. Connexin proteins are usually designated with numerical
sufﬁxes referring to their calculatedmolecularweight inkilodaltons (e.g.,
connexin43 or Cx43). Connexins have a cytoplasmic N-terminus, four
hydrophobic membrane-spanning domains, two conserved, extracellu-
lar domains, a loop between transmembrane domains 2 and 3, and a
cytoplasmic carboxy-terminal tail region that is diverse in size and
sequence. Structural studies indicate that the N-terminus plays a role in
channel function and gating [7–10] while the extracellular domains are
involved in hemichannel docking between cells [11]. In general, the
C-termini of connexins can be phosphorylated and mediate interactions
with other proteins as discussed below.
Gap junctions play signiﬁcant regulatory roles in embryonic
development, electrical coupling, metabolic transport, apoptosis,
differentiation, tissue homeostasis and carcinogenesis [5,6,12]. Con-
nexins are differentially expressed in tissues with some being
signiﬁcantly expressed in only a few tissues and some, like Cx43,
being more widespread [3,13]. Given their diverse tissue expressions,
mutation of different connexins can yield a wide range of diseases
including hereditary deafness, cataracts and a variety of skin diseases
[5,6]. Mutation of the Cx43 gene (GJA1) can cause oculodentodigital
disease (ODDD), a rare syndrome that can result in small eyes,
underdeveloped teeth, and syndactyly [14]. A mouse strain (Gja1Jrt/+)
carries the dominant loss-of-function Cx43 mutation, Cx43G60S and
displays features of ODDD [15]making it a useful model to probe Cx43
function [16,17]. Replacement of Cx43 with a truncated version
(Cx43K258Stop) lacking the C-terminal, cytoplasmic tail region
yielded mice that died shortly after birth due to an epidermal barrier
defect [18], not the heart defect that is present in Cx43 deﬁcient mice
[19]. The C-terminal region has been shown to have multiple sites of
phosphorylation and protein interaction and hence is likely involved
in Cx43 regulation [20].
Connexin phosphorylation has been correlated with changes in
gap junction assembly, stability and channel properties [20–24].
Although treatment of cultured cells with inhibitors of phosphatases
often does not appear to affect gap junction communication, multiple
reports indicate that phosphatases may regulate connexin function in
certain instances, particularly during dynamic regulation during
cardiac ischemia [25–27]. Furthermore, dephosphorylation might be
linked to Cx43 relocalization during ischemia [25]. Where examined,
most members of the connexin family of proteins have been shown to
be substrates for kinases, and, given that tissues can express multiple
connexins, a single cell can probably express multiple phosphorylated
connexins. Up until the last several years, most connexin phosphor-
ylation-related research was based on cell culture models as detailed
in many recent reviews [21–23,28–30]. In contrast, this review
focuses on connexin phosphorylation in tissues and offers speculation
on the role that these events play in tissue function. These studies are
now possible because phosphorylation state speciﬁc antibodies have
become available for several phosphorylation sites in Cx43.
2. Phosphorylation of Cx43
Cx43 has a half-life in the range of 1–3 h in cultured cells or in
tissues [31–35]. This fast turnover rate presumably implies a need for
a high level of post-translational regulation of gap junction/connexin
function. The early work of Musil and Goodenough, the Lau laboratory
and several other investigators have shown that Cx43 is differentially
phosphorylated throughout its life cycle [31–33,36–40]. Cx43 typi-
cally demonstrates multiple electrophoretic isoforms when analyzed
by polyacrylamide gel electrophoresis that can be collapsed by
phosphatases to a faster migrating non-phosphorylated isoform.
Phosphoamino acid analysis indicates that the majority of the
phosphorylation events in homeostatic cells occur on serines
[39,41–43], although tyrosine phosphorylation has been observed
when pp60src is activated [32,44]. In Cx43, only the C-terminal region
of Cx43 appears to be phosphorylated but Cx36 and Cx46 can bephosphorylated in the intracellular loop region [45,46]. Cx43 does not
contain serine residues in its intracellular loop region, and we are not
aware of any reports of phosphorylation near the N-terminus of
connexins.
Activation of different kinase systems has been shown to regulate
connexin biology. Reports indicate that Cx43 can be phosphorylated on
at least 14 of the 21 serines and 2 of the tyrosines in the cytoplasmic tail
region (amino acids 245–382). Low levels of threonine phosphorylation
have been observed in connexins, including Cx43 [47] and Cx37 [48],
but, to our knowledge, have not been investigated further. PKA
activation leads to upregulation of several connexins including Cx43
and Cx50 [46,49,50], although Cx43 is a poor direct PKA substrate
[51,52], so other kinase systems are likely involved. Several residues
in tandem serine repeat regions near the C-terminus of Cx43 can be
phosphorylated (i.e., serines 365, 368, 369 and 373) in response to
follicle-stimulating hormone, probably at least partially through a
PKA-mediated mechanism [53]. PKC has been shown to phosphorylate
Cx43 at S368 and S372 in vitro and increased phosphorylation of S262
and S368 is seen in response to TPA [52,54,55]. S262 phosphorylation
has been linked to increased cellular proliferation through an unknown
mechanism [56] while S368 phosphorylation has been shown to
underlie the TPA-induced reduction in intercellular communication
[54]. Cx43 phosphorylation at S368 results in a reduction in unitary
channel conductance with 50pS channels favored over 100pS channels
[57]. PKC-mediated phosphorylation of puriﬁed recombinant Cx43
abolished sucrose and Lucifer Yellow permeability and led to a
conformational change in Cx43 [58]. PKCα and ε were found to
associatewith Cx43 in cardiomyocytes [59]. PKCγ interactswith Cx43 in
lens epithelial cells [60]. Fibroblast growth factor-2, which decreases
cardiomyocyte gap junctional permeability and increases Cx43 phos-
phorylation, increased colocalization of PKCε with Cx43 [61].
Casein kinase 1, particularly the δ isoform, has been shown to
interact with and phosphorylate Cx43 [62]. p42/44 MAPK phosphory-
lates Cx43 at serines 255, 279 and 282 [43] and causes reduced gap
junction channel open time [63]. Certainly other kinases phosphorylate
Cx43, and it appears to be possible formultiple kinases to phosphorylate
the same residue. For example, serine 255 has been reported to be
phosphorylated by both MAPK and cdc2 [43,64]. Thus, considerable
evidence indicates that Cx43 is a highly phosphorylated and a highly
regulated protein.3. Phosphorylation status speciﬁc antibodies
While the overall phosphorylation status of connexins within tissue
preparations canbeprobedby SDS-PAGEand analytical techniques such
as mass spectrometry, localization of in situ phosphorylation usually
requires the use of phosphorylation status speciﬁc antibodies. Based on
its early availability, a monoclonal antibody that binds primarily to the
P0 isoform of Cx43 (Zymed/Invitrogen, 13–8300) [65] has been widely
used to probe in vivo Cx43 phosphorylation in a variety of tissue
preparations [66–70]. The fact that this antibody binds predominately to
the P0 form indicates that the phosphorylation event(s) that eliminates
binding might be a key early regulatory event in Cx43 life cycle. The
immunizing peptide that produced this antibody contained residues
360–376, but the speciﬁc unphosphorylated serines that comprise the
epitope are unknown. The antibody can recognize other minor Cx43
bands in untreated cells and recognizes multiple bands upon TPA
treatment [71], due to changes in phosphorylation outside this
antibody's epitope. Another monoclonal antibody speciﬁc to a depho-
sphorylated formof Cx43, termedCT1,has both overlappinganddistinct
properties and was epitope mapped to non-phosphorylated S364/S365
[72]. Phosphorylation at both S364 and S365 appear to be important
regulatory events [51,73] and the latter involves phosphorylation that
results in SDS-PAGE migration at the P1 position [73], an isoform
distinctly not recognized by 13–8300 or CT1 [71,72]. Thus, either or
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binding.
Several phosphospeciﬁc antibodies to Cx43 have been developed
recently and some are commercially available. One of the ﬁrst
commercially available phosphospeciﬁc antibodies was to residue
S368, a PKC phosphorylation site on Cx43. Now close to a dozen
companies sell antibodies to this same site and the adjacent serine at
369. In addition, at least three companies produce phosphospeciﬁc
antibodies to S262 and one to S255. A few other commercial
antibodies have been made to additional sites but for the most part,
at least in our hands, these antibodies do not perform well. Several
phosphospeciﬁc antibodies have been prepared by individual in-
vestigators including ones to sites at S279/282 [74,75], Y247 [76],
Y265 [76], S306 [77], and S325/328/330 [78]. These antibodies are
beginning to reveal some of the overlapping roles of Cx43 phosphor-
ylation in gap junction function. For example, src-mediated down-
regulation of gap junctions has been well described, and Cx43 has
been shown to be directly phosphorylated by src at Y247 and Y265
[44,47,76,79,80]. However, data generated in differentmodel systems,
using inhibitors of various kinase pathways have led to some
controversy as to how src activation actually downregulates gap
junction communication. Use of a combination of several phosphos-
peciﬁc antibodies showed that activation of v-src leads not only to
phosphorylation on Y247 and Y265, but also phosphorylation at S262,
S279/282, and S368 and leads to a decrease in phosphorylation at
S364/365 [76]. Thus, oncogenic src activation leads to apparent
stimulation of at least src, MAPK and PKC phosphorylation of Cx43
making studies focused on single pathways less conclusive.
To our knowledge, Cx36 is the only other connexin to which
phosphospeciﬁc antibodies have been prepared. PhosphorylationFig. 1. Brain shows phosphorylation at S365, S325/328/330 and S368. (A) For SDS-PAGE andW
tissue was pulverized in the presence of sample buffer containing protease and phosphatase
brains 1 and 2 (one in each lane) were run on 10% PAGE, blotted and probed with NT1 antib
and S325/328/330 (pS330) [73]. (B) Immunoﬂuorescence of OCT embedded frozen sections
red) antibodies. Immunohistochemistry of formalin-ﬁxed, parafﬁn-embedded tissue section
membranes (brown) for total Cx43 (C) and phospho-S368 (D). Phospho-S368 levels appeastatus dependent antibodies to S110 and S276 have been used to
study retinal tissue preparations under different lighting conditions
and to examine the role of different kinase systems [46,81].
4. Connexin phosphorylation in brain tissue
Gap junctions play a critical role in cell–cell communication in the
nervous system. They are thought to maintain brain homeostasis by
allowing electrical coupling between neurons and regulating neuro-
nal network activity [82,83]. In brain, Cx43 is the dominant gap
junction protein expressed in astrocytes and is abundantly expressed
in Bergmann glial cells in the cerebellum [84]. Many diverse functions
have been attributed to Cx43 and gap junctional communication
in the brain, one of which is apparent in Cx43-null [85] and Cx43-C-
terminus truncated [86] mutant mice that show delays in neuronal
migration.
Levels of astrocytic gap junctional intercellular communication are
thought to be dynamic and subject to regulation by a variety of factors.
However, little published information is present about connexin
phosphorylation in intact tissue. We analyzed adult mouse brain for
total Cx43 and Cx43 phosphorylated at speciﬁc serine residues. Using
immunoﬂuorescence and Western blot techniques, examination with
antibodies speciﬁc for phosphorylation at S365 and S325/S328/S330
showed clear evidence of phosphorylation of Cx43 in the brain in
apparent typical punctate gap junctional structures and via SDS-PAGE,
respectively (Fig. 1). Additionally, using immunohistochemical stain-
ing, we also observed that apparent gap junctional staining for
phospho-S368 preferentially occurred in cerebellum (Fig. 1D).
Cx43 has been shown to increase in human brain as a result of
ischemia [87] and in the hippocampus of patients with epilepsy [88],estern blot, twomouse brains were quickly removed and frozen in liquid nitrogen. The
inhibitors to prevent dephosphorylation during tissue homogenization. Samples from
ody to total Cx43 or antibodies to Cx43 phosphorylated at S368 (pS368), S365 (pS365)
of brain using total Cx43 (Cx43IF1 [72]—in green) and phospho-S325/328/330 ([78]—in
s stained with Hematoxylin/Eosin showing cerebellar cells staining at opposed plasma
red to be highest in the cerebellar regions of the brain. Bars are 20 μm.
1988 L. Márquez-Rosado et al. / Biochimica et Biophysica Acta 1818 (2012) 1985–1992but at this point phosphorylation of Cx43 has not been analyzed in
detail. Since protein phosphorylation has been shown to be involved
in a wide variety of neurophysiological events, it will be interesting to
see whether the phosphorylation status of Cx43 could be affected and
regulate responses under ischemic or inﬂammatory conditions and in
neurological disorders.
5. Connexin phosphorylation in cardiac tissue
Impulse propagation in the heart occurs through gap junctions and
disruption or dysregulation of gap junctions is a signature of many
cardiac pathologies [89]. Normally gap junctions are found in
abundance at a distinct and specialized structure at the ends of
myocytes referred to as the intercalated disc [90,91]. This structure
also contains a high concentration of desmosomes and adherens
junctions that provide mechanical stability to cardiac tissue [92].
Cx43, Cx40, and Cx45 can all be found in heart and are expressed in
a spatially distinct manner (reviewed in Ref. [93]). Cx43 is the
dominant gap junction component in the ventricle and the primary
connexin where phosphorylation has been analyzed. Across species,
essentially all Cx43 in the ventricle is highly phosphorylated resulting
in a conformation that exhibits a migration shift in SDS-PAGE that can
be eliminated by phosphatase treatment [25,67,94,95]. Analysis with
phosphospeciﬁc antibodies show that this migratory isoform of Cx43
is phosphorylated on S365 and S325/S328/S330 and immunohisto-
chemical analysis of mouse heart conﬁrms that phosphorylation of
Cx43 at these sites occurs at the intercalated disc [73,78]. Indeed,
phosphorylation of these sites has been shown to be responsible for
inducing the conformational change resulting in the migration shift
[62,73,78,96]. S306 phosphorylation has also been shown at the
intercalated disc in rat heart [77]. Several additional phosphorylation
sites in cardiac tissue have been identiﬁed via mass spectrometry [97]
though the location and prevalence of these events have not yet been
elucidated.
Given the integral nature of gap junctions in cardiac function, it is
not surprising that changes in connexin expression and gap junction
remodeling are a feature of many cardiac pathologies. Typically, this
includes a decrease in Cx43 at the intercalated disc and a shift to the
lateral edges of the myocyte, a process referred to as lateralization
(e.g. Ref. [25]). SDS-PAGE analysis of Cx43 from compromised hearts
of many etiologies show a shift to the faster migrating forms of the
protein, indicating a change in its phosphorylation state [98]. Changes
in Cx43 have been implicated in altering susceptibility to arrhythmia
under various conditions as well as directly impacting damage
occurring upon myocardial infarction (MI). It is unclear at this point
whether these outcomes are related or more likely reﬂect different
roles for Cx43 in maintaining cardiac health.
A mechanistic link demonstrating a role for phosphorylation on
S325/328/330 in gap junction remodeling and arrhythmic suscepti-
bility is clearly shown through studies using Cx43 knock-in mice
where these sites have been mutated to glutamic acid, to mimic
phosphorylation, or alanine, to eliminate phosphorylation, at those
sites [96]. Transverse aortic constriction in wild type and
S325/328/330A mice resulted in gap junction remodeling while
S325/328/330E maintained Cx43 at the intercalated disc. In addition,
ventricle tachycardia induction by programmed electrical stimulation
showed distinct phenotypes for the mutants where S325/328/330E
mutants were resistant to ventricular arrhythmias while the
S325/328/330A were more susceptible to arrhythmias than wild
type animals. Thus, these mice prove that Cx43 phosphorylation
status at these sites is necessary for adaptive responses in cardiac
tissue to change in physiologic parameters.
Changes in Cx43 phosphorylation and localization have also been
studied during ischemia. This is especially relevant as Cx43 plays a
critical role in the phenomenon of preconditioning wherein short
bouts of ischemia preceding a longer ischemic interval can actuallyprotect the heart from damage [99]. This is illustrated by the fact that
mice that are heterozygous for a null mutation in Cx43 do not respond
to preconditioning [100–102]. Though interestingly, these animals
exhibit smaller infarcts in response to coronary artery occlusion [103].
Cx43 appears to mediate these types of cardiac effects through a
complex interplay of gap junction communication dependent and
independent means. While it is clear that preconditioning preserves
Cx43 localization and phosphorylation, as evidenced by its continued
presence at the intercalated disc and maintenance of the slow
migrating isoforms [104], an additional role for Cx43 in the
mitochondria and regulation of reactive oxygen species during
preconditioning is also emerging [105]. A small fraction of cellular
Cx43 has been shown to fractionate withmitochondria and appears to
be enriched in the slow migrating isoforms [106], though speciﬁc
phosphorylation events have not been studied. The role of Cx43 in the
preconditioning response appears to be complex, involving the
mitochondria and reactive oxygen species regulation, gap junction
permeability and Cx43 localization. An interesting example of the
complexity involved in these processes is shown in mouse hearts
where the Cx43 gene is replaced with Cx32, which likely does not
translocate to the mitochondria; this Cx43 heterozygote maintains
the ability to be preconditioned through short bouts of ischemia but is
not protected by diazoxide, a drug which directly impacts mitochon-
dria function [107].
A few groups have begun to dissect the individual phosphorylation
sites and kinase systems involved in these events. The interaction of
Cx43 with PKC has received the most attention as PKC has also been
shown tobenecessary forpreconditioning [108,109], andPKCactivation
can result in phosphorylation at S368 and S262 [54–56]. Immunoblot
analyses from several labs show that phosphorylation on S368 is
increased after ischemia [57,110–113] regardless of preconditioning.
However, immunoﬂuorescence analysis of cardiac tissue showed that
therewas less pS368 at the intercalated disc after preconditioning [110].
Since S368 phosphorylation has clearly been shown to modulate gap
junction permeability [54,57] this site may play a role in mediating gap
junction communication dependent aspects of protection. In rat hearts,
phosphorylation on S262 was correlated with a preconditioned
phenotype [111,112]. In addition, when a S262Amutant was expressed
in cultured cardiomyocytes these cells were prone to cell death upon
ischemic-type injury. Signal transduction through MAPK cascades, in
particular p38 MAPK and ERK1/2, have also been examined. In rat
hearts, ischemia led to an increase in p38 MAPK activity and an
associated increase in interaction with Cx43 that was attenuated with
preconditioning [114]. However, in pig hearts immunohistochemistry
showed increased interaction between Cx43 and p38 MAPK with
preconditioning [95]. Interestingly, another group studying terminal
differentiation of cardiomyocytes observed a positive feedback loop
linking p38MAPK activation tomitochondrial translocation of Cx43 and
ROS generation [115]. ERK1/2 has also been implicated in controlling
Cx43 translocation to themitochondria and promoting survival in stem
cells [116]. Thus, the interplay between these various kinase systems
seem to be important in regulating multiple aspects of Cx43 biology.
As emphasized above, dephosphorylation of Cx43 has repeatedly
been shown to correlate with cardiac pathogenesis across species. In
addition to the migration shift, the two monoclonal antibodies used
to detect “non-phosphorylated” Cx43, Zymed/Invitrogen 13–8300
and CT1 [72] have been used in ischemic tissues. The CT1 antibody
begins to detect this dephosphorylation event within 5 min of
ischemia, well before the levels are sufﬁcient to detect the migration
shift by an antibody to total Cx43. This same antibody also shows
increased signal for Cx43 after 30 min of ischemia at both the
intercalated disc and in lateralized regions of the myocytes (Fig. 2).
Similar data has been seen using the 13–8300 antibody [25]. Signal
from this antibody is also diminished when rat hearts are treated
with FGF-2 before ischemia, a situation that mimics preconditioning
[111]. Interestingly, this study included a reperfusion step, during
Fig. 2. Gap junction remodeling in heart occurs in response to ischemia. Mouse hearts were excised and immediately ﬁxed in formalin (CON) or ﬁrst incubated without perfusion in
non-oxygenated PBS for 30 min (ISCHEMIA). Parafﬁn embedded sections were co-labeled with a rabbit antibody to Total Cx43 (Sigma-Aldrich, St. Louis, MO) and a mouse antibody,
CT1, which recognizes Cx43 unphosphorylated on S364/365 (FHCRC, Seattle, WA). Overlay panel shows the Total Cx43 antibody labeled with Alexa 546-conjugated secondary
antibody in red and CT1 labeled with Alexa 488-conjugated secondary antibody in green.
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increase in the slower migrating phosphoform. Similarly, another
ischemia-reperfusion study indicated that the ability of a heart to
recover contractile activity during reperfusionwas strongly correlated
with this same loss of 13–8300 and gain of the slower migrating
phosphoform recognized by an antibody to total Cx43 [25]. These data
indicate a potential but important role for a phosphatase in Cx43
regulation during ischemia and are consistent with a report showing
that an inhibitor of PP1 (protein phosphatase1)-like phosphatases
could inhibit ischemia-induced dephosphorylation of Cx43 [26]. These
data, in combination with the knock-in mouse data, indicate that the
phosphorylation sites and the kinases responsible for homeostatic
regulation of Cx43 could be major players in cardiac pathogenesis.
6. Connexin phosphorylation in endothelial tissue
Connexins expressed within the vasculature include Cx37, 40, 43
and 45 [117]. Cx43 phosphorylation has been implicated in affecting
vessel biology through both gap junction dependent and independent
means. For example, in resistance vessels, heterocellular communi-
cation between vascular smooth muscle cells (VSMC) and endothelial
cells (ECs) are thought to occur through a specialized actin based
structure called the myoendothelial junction (MEJ) [118,119].
Electrical and dye coupling through the MEJ can be differentially
regulated in different tissues and two complementary studies have
shown that this can be regulated via Cx43 phosphorylation [118,120].
Isakson, et al. showed the presence of Cx43 phosphorylated at S368 at
the MEJ in mouse cremaster arterioles where there is little to no
coupling. This is in contrast to rat mesentery where coupling occurs at
the MEJ and Cx43 is found without S368 phosphorylation, consistent
with the role S368 phosphorylation plays in channel gating. This
ﬁnding was explored further through in vivo dye transfer assays
performed on mouse cremasters in the presence or absence of pCPT, a
cAMP analog [120]. cAMP has long been known for its ability to
increase gap junctions and intercellular communication [49,50]. In
this case, activation of cAMP on cremaster arterioles led to a loss of
S368 phosphorylation and a signiﬁcant increase in the ability of
VSMCs to transfer dye to ECs. This relationship between phosphor-
ylation on S368 and heterocellular communication was further
corroborated in vitro using a vascular cell co-culture model that also
looked at the movement of second messengers, inositol tri-phosphate
(IP3) and calcium. In this case phosphorylation on S368 could inhibitIP3 transfer while allowing calcium movement, which is, again,
consistent with a role for S368 in modulating channel gating.
Cx43 phosphorylation has also been shown to change during
atherogenesis where minimally modiﬁed low density lipoproteins, the
oxidative products of low density proteins, accumulate in vessel walls
forming a plaque [121]. Components of these complexes are thought to
mediate changes in VSMCs, including increased proliferation, and
contribute to disease. In the ApoE−/−mouse, a model of atherogenesis
that is prone to artherogenic plaques, total Cx43 expression was
diminished in carotid arteries [122], while phosphorylation on S368 and
S279/282 were signiﬁcantly increased. Using speciﬁc biologically active
derivatives ofminimallymodiﬁed low density lipoprotein embedded in a
pluronic gel, Johnstone et al. were able to distinctly induce these
phosphorylation events in the carotids of normal mice. Application of
1-palmitoyl-2-oxovaleroyl-sn-glycero-3-phosphorylcholine (POVPC)
was able to induce S279/282 phosphorylation while 1-palmitoyl-2-
glutaroyl-sn-glycero-3-phophorylcholine (PGPC) induced S368 phos-
phorylation. Notably, POVPC, and not PGPC, was able to induce
proliferation in VSMCs, as well. As the authors point out, it is interesting
to speculate that phosphorylation on S279/282 could help mediate this
proliferative phenotype, but further work will be required to explore this
hypothesis.
7. Connexin phosphorylation in epithelial tissue
Epithelium is an avascular tissue deﬁned by a polarized cell
morphology. Epithelial tissues encapsulate many of the structures and
organs in vertebrates. Cx43 is expressed in many epithelial tissues
[13]. Phosphorylation of Cx43 at S368 has been detected in intestinal
epithelial cells of mice deﬁcient in theMDR1α gene [123]. MDR1α−/−
mice develop spontaneous chronic colitis, a chronic inﬂammatory
injury of the intestinal epithelial cell barrier resembling ulcerative
colitis. Ey et al. detected elevated pS368 by Western blotting of colon
tissue fromMDR1α−/−mice sacriﬁced on day 67 postpartum, relative
to age matched wild type control mice. The observed hyperpho-
sphorylation of Cx43 at S368 could be prevented by treating
MDR1α−/− mice with a TLR2 agonist.
Phosphorylated Cx43 has also been reported in mammary tissue.
Gould et al. developed an antiserum (SA226P) shown to react with
S279/282 of Cx43 when phosphorylated by MAPK [124]. In normal
adult human breast, Cx43 phosphorylated at S279/S282 is detected in
myoepithelial cells. In a mouse model of the human Cx43-related
1990 L. Márquez-Rosado et al. / Biochimica et Biophysica Acta 1818 (2012) 1985–1992disease occulodental digital dysplasia, Plante and Laird [125] observed
a decrease in the highly phosphorylated forms of Cx43 in the
mammary glands of Gja1Jrt/+ mice when compared to wild type
littermate controls. Additionally, Plante and Laird observed delayed
development of the mammary ducts and a defect in milk ejection in
these mice.
Epidermis is a stratiﬁed surface epithelium and functions as a
dynamic organ capable of responding to injury and environmental
insults. Several connexins are expressed in epidermis with Cx43
predominating and Cx26, Cx30, Cx30.3, Cx31, Cx40 and Cx45 expressed
atdifferent levels indifferent regions and in response todifferent stimuli
[126,127]. In addition to providing a barrier function and protection
from ultraviolet light, epidermis is capable of responding to and
repairing injury to the organ. Connexin proteins are known to play a
role in this repair process during which they presumably undergo
phosphorylation by a diverse array of kinases. Phosphorylated S368was
observed to be elevated in embryonicmouse skin, whereas adultmouse
epidermis exhibited low to moderate levels localized to the suprabasal
cell layers [128]. This expression pattern of low to moderate levels of
phosphorylated S368 is also found in human adult epidermis. However,
uponwounding, Cx43phosphorylation at S368 is elevated speciﬁcally in
the basal cell compartment proximal to the wound margin [129]. The
observed increase in S368 phosphorylation reaches maximal levels in
skin at 24 h post wounding and returns to baseline by 72 h [129].
8. Connexin phosphorylation in other tissues and
during carcinogenesis
A physiological role for in vivo Cx43 phosphorylation has been
demonstrated in mouse ovarian follicles. Cx43 is the most prevalent
connexin in the ovary [130], connecting granulosa cells within each
follicle. In response to luteinizing hormone (LH) from the pituitary,
which signals meiosis to resume in oocytes, Cx43 in granulosa cells
becomes phosphorylated [131], through a MAPK-dependent mecha-
nism [132] on serines 255, 262, and 279/282 [75]. These events cause
a decrease in gap junction permeability between granulosa cells,
contributing to the resumption of meiosis in the oocyte. Phosphor-
ylation at these sites is transient, and by 5 h after LH treatment,
serines 255, 262, and 279/282 are no longer phosphorylated [75]. In
ovarian follicles that have not yet been exposed to LH, there are
several phospho-isoforms of Cx43 [75,131]. The signiﬁcance of this
phosphorylation is not clear, but it will be interesting to investigate
further.
Cx50 is expressed in ﬁber cells of the lens of the eye and has been
reported to be phosphorylated in vivo on S395 [133]. This study
showed that PKA is likely the kinase that phosphorylates this site in
vivo and that phosphorylation enhances gap junction and hemi-
channel function [133]. The level of Cx43 phosphorylation in the
cornea at S368 appears to be developmentally regulated with distinct
differences in embryonic (high) and adult (low) tissue [128].
Immunohistochemical investigation of mouse skin neoplasia for
total Cx43 and Cx43 phosphorylated at S368 in DMBA/TPA-induced
mouse skin showed dramatic changes during progression. An increase
in total Cx43 and phospho-S368 antibody reactivity was observed in
junctional structures in hyperplastic skin compared with more
aggressive tumors that exhibited decreased levels and nonfunctional,
cytoplasmic localization of Cx43 [128]. Upregulation of Cx43
phosphorylated at S279/282 was observed in breast hyperplasias
and carcinomas [124].
9. Concluding remarks
Studies performed in tissue culture systems have clearly shown
that connexins and gap junction biology are affected by phosphory-
lation. However, until recently, little was known about whether these
phosphorylation events actually occur in tissue and whether theyaffect tissue function. Phosphorylation status speciﬁc antibodies have
revolutionized the ﬁeld of cell biology, and the few commercially
available phosphospeciﬁc antibodies have already shown that Cx43
phosphorylation is regulated in vivo. More antibodies will begin to
give us an overall view of how different signaling pathways interact to
affect tissue biology. In addition, generation of knock-in mice
expressing phosphorylation site mutants will allow us to see how
connexin phosphorylation impacts tissue function. As these tools
allow a better understanding of the consequences of connexin
phosphorylation and an increased appreciation of the consequences
of connexin phosphorylation on its interactions with other proteins,
we expect future studies will show that connexin phosphorylation
plays key biological roles critical for proper tissue function.
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